OCULOCULAR THERAPEUTIX, INC同业对比
OCULAR THERAPEUTIX, INC 与Pharmaceutical Preparations的逐项对比:市值、估值、增长、盈利能力、质量与总回报,以及在同业组内的排名。所有数值均由引擎从 SEC 申报与延迟行情计算,排名仅为组内排序位置 —— 描述性数据,非投资建议。
完整同业对比
同业组:同 SIC 行业分类 (Pharmaceutical Preparations)| 公司 | 市值 | 市盈率(TTM) | 市净率 | 市销率 | 营收同比增长 | 净利同比增长 | 息税前利润率 | 净资产收益率 | 投入资本回报率 | 皮氏 F 值 | 一年总回报 | 股息率 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| OCUL本股 | $2.2B#9 | — | 4.3x#7 | 42.9x#9 | -18.5%#10 | -37.4%#9 | -519.8%#10 | -51.1%#11 | — | — | -16.4%#13 | — |
| SUPN | $2.5B#2 | — | 2.4x#3 | 3.5x#5 | 8.6%#6 | -152.2%#14 | -8.7%#4 | -3.7%#4 | -5.0%#4 | — | -4.0%#12 | — |
| MLYS | $2.5B#1 | — | 4.5x#8 | — | — | 13.0%#3 | — | -28.1%#9 | -41.3%#6 | — | -24.1%#14 | — |
| VRDN | $2.5B#3 | — | 3.7x#6 | 34.9x#7 | 23359.9%#1 | -26.9%#8 | -512.9%#9 | -51.7%#12 | -54.5%#7 | — | 17.3%#10 | — |
| HRMY | $2.5B#4 | 13.7x#2 | 2.5x#4 | 2.8x#4 | 21.5%#5 | 9.1%#6 | 24.0%#2 | 15.9%#1 | 25.5%#1 | 4#1 | 32.2%#8 | — |
| VERA | $2.4B#5 | — | 6.0x#10 | — | — | -96.9%#11 | — | -73.5%#13 | -72.7%#8 | — | 37.2%#6 | — |
| NKTR | $2.4B#6 | — | 2.6x#5 | 42.9x#8 | -43.9%#11 | -37.8%#10 | -253.7%#7 | -18.2%#6 | -14.0%#5 | — | 35.7%#7 | — |
| SLS | $2.3B#7 | — | 16.8x#15 | — | -100.0%#12 | 13.0%#4 | — | -19.5%#8 | — | — | 576.7%#1 | — |
| PVLA | $2.2B#8 | — | 10.3x#14 | 52.3x#10 | 65.3%#4 | -139.3%#12 | -90.2%#6 | -19.2%#7 | — | — | 174.6%#2 | — |
| PBH | $2.2B#10 | 13.0x#1 | 1.1x#1 | 2.0x#3 | -4.3%#9 | -11.3%#7 | 28.4%#1 | 9.9%#2 | 5.9%#2 | 4#1 | -27.4%#15 | — |
| GENB | $2.1B#14 | — | 4.7x#9 | — | — | — | — | 0.0%#3 | — | — | — | — |
| TRVI | $2.2B#12 | — | 6.7x#11 | — | — | 10.7%#5 | — | -13.3%#5 | — | — | 90.2%#3 | — |
| NUVB | $2.2B#13 | — | 8.5x#13 | 34.3x#6 | 699.0%#2 | 64.0%#2 | -338.7%#8 | -80.6%#14 | -87.4%#10 | — | 87.2%#4 | — |
| SRPT | $2.2B#11 | — | 1.4x#2 | 1.2x#2 | 4.3%#8 | -403.3%#15 | -37.5%#5 | -46.7%#10 | -73.0%#9 | — | 20.2%#9 | — |
| BHC | $2.1B#15 | — | — | 0.2x#1 | 6.7%#7 | 441.3%#1 | 17.7%#3 | — | 3.6%#3 | — | -2.4%#11 | 16.7%#1 |
| ZBIO | $2.1B#16 | — | 8.5x#12 | 208.8x#11 | 100.0%#3 | -140.6%#13 | -3830.6%#11 | -152.9%#15 | -296.6%#11 | — | 67.7%#5 | — |
数值来自 SEC 申报与延迟行情;排名仅为该组内的排序位置 —— 描述性数据,不构成评级或建议。 数据构建于 2026-09-17。
数据来自 SEC XBRL 申报与延迟行情 · 排名为组内排序 · 仅供参考 · 非投资建议